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Abstract: The care of older patients with cancer is becoming increasingly complex.
Common challenges for this population include management of comorbidities, safe transi
tions of care, and appropriate medication use. In particular, polypharmacy—generally
defined as the regular use of five or more medications—and inappropriate medication use
can lead to adverse effects and poor outcomes in older adults with cancer, including falls,
hospital readmissions, cognitive impairment, poor adherence to essential medications, che
motherapy toxicity, and increased mortality. Managing polypharmacy across different cancer
care settings is often challenging. Providers face barriers to safe and successful medication
management that may include lack of time, absence of reimbursement, underappreciation of
the scale of polypharmacy-related harm, lack of ownership of deprescribing efforts, and poor
communication across care settings. Existing literature on managing inappropriate medica
tion use and polypharmacy in older adults with cancer has often focused on ideal state
settings in which resources are plentiful and time is purposefully allocated for medication
interventions. This paper presents a narrative, rather than a systematic review, of studies
published in the past decade that provided detailed information on medication management
and polypharmacy across cancer care settings. This review aims to also summarize different
healthcare provider roles in taking action against inappropriate medication use and poly
pharmacy in older adults with cancer.
Keywords: geriatric oncology, polypharmacy, potentially inappropriate medication,
medication management, deprescribing, cancer care setting, interprofessional team
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The care of older patients with cancer is becoming increasingly complex. This
complexity may comprise management of comorbidities, safe transitions of care,
and appropriate medication use. In particular, polypharmacy—generally defined as
the regular use of five or more medications—and inappropriate medication use can
lead to adverse effects and poor outcomes in older adults with cancer, including
falls, hospital readmissions, cognitive impairment, poor adherence to essential
medications, chemotherapy toxicity, and increased mortality.1
Healthcare experts have noted that addressing such medication use represents an
important opportunity to improve medical care for older adults.2 However, mana
ging polypharmacy across different cancer care settings is often challenging.
Barriers for providers to safely and successfully manage medications include lack
of time, absence of reimbursement, underappreciation of the scale of polyphar
macy-related harm, lack of ownership of deprescribing efforts, and poor commu
nication across care settings.3,4 Many of these challenges can be abated by the
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introduction of clinical pharmacy services, with several
studies showing positive benefits when pharmacists are
added to the care team for older adults with cancer.5,6
Existing literature on managing inappropriate medica
tion use and polypharmacy in older adults with cancer
has often focused on ideal state settings in which
resources are plentiful and time is purposefully allocated
for medication interventions. In real life, this ideal state is
often not feasible in different cancer care settings. For
instance, while larger academic medical centers may
have multiple dedicated pharmacists to conduct medica
tion reviews, small hospitals may not. Thus, our paper
presents a narrative, rather than a systematic review, of
studies published in the past decade that provided
detailed information on medication management and
polypharmacy across cancer care settings. These studies
included cohorts of patients diagnosed with solid tumor
malignancies, hematologic malignancies and surgical
oncology patients.
With our narrative review, we aim to summarize
different healthcare provider roles in taking action
against inappropriate medication use and polypharmacy
in older adults with cancer (Box 1 describes how to use
this review). It is the first review of its kind to summar
ize potential clinician roles in evaluating polypharmacy
in various cancer care settings. Each section describes
nuances and differences in priorities within each care
setting aimed at combating polypharmacy in older adults
with cancer as detailed in Table 1. Along with noting
differences in care setting priorities, this paper empha
sizes the importance of examining individual patient
context when making medication-related decisions. For
older adults with cancer, geriatric syndromes (eg, falls,
frailty, cognitive impairment, mobility issues) and the
issue of chronologic age versus functional age can be
directly aligned with polypharmacy assessments and
deprescribing decisions. Todd et al7 recently explored
patient context as it relates to deprescribing recommen
dations and developed a conceptual framework called
“the deprescribing rainbow” that considers clinical, psy
chological, social, financial, and physical determinants
for assisting with deprescribing decisions. The global
themes of the deprescribing rainbow framework high
light the heterogeneity of the older adult population and
acknowledge the evolving care needs of the individual
patient; these themes are consistent with the established
role of person-centered care in managing medications in
older adults with cancer.7
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Box 1 How to Use This Review
● Review the entirety of this paper or jump to the applicable section
according to individual discipline or work setting (eg, a nurse
practicing in outpatient clinics may obtain the most benefit from the
text and corresponding tables in the “ambulatory setting” section).

● Each row within the table outlines the various roles of clinicians in
different care settings and indicates where overlap of practice and
concepts exist.

● Consider the bottom line recommendation box a “call to action”
on what the authors consider the most evidence-based area or idea
worth exploring in future research on polypharmacy in older adults
with cancer.

● Clinicians are encouraged to make simple changes and adopt what
makes sense for their practice site. Applying all recommendations in
a specific care setting may not be feasible initially.

Finally, this review attempts to identify gaps in
knowledge and lay out areas of interest for future
research efforts. It should be noted that even within
seemingly identical care settings, there may be unique
challenges that prevent optimal services. One example is
use of screening tools to identify polypharmacy and
potential inappropriate medication (PIM) use. While
screening tools are not required for identifying polyphar
macy and PIMs, they can certainly streamline the pro
cess. For some clinicians, awareness and implementation
of a screening tool may not be a part of their routine
workflow while caring for older adults with cancer. It is
also important to note that not all screening tools are
specific to older adults with cancer, and some tools are
more user friendly than others. Existing data support the
application of three medication screening tools for older
adults with cancer: Beers Criteria, Medication
Appropriateness Index (MAI), and the Screening Tool
of Older Persons’ Prescriptions (STOPP). Beers Criteria
and STOPP are both explicit screening tools that help
clinicians quickly screen for inappropriate therapies
based on potential medication-induced harm or diseasemedication discrepancies. The MAI is an implicit scor
ing-based tool that helps determine appropriateness based
on a defined set of criteria (eg, indication, efficacy,
dosage, directions, cost, drug–drug interactions, drug–
disease interactions, and medication duplication); each
medication screened with the MAI is subsequently
deemed to be inappropriate, marginally appropriate, or
appropriate. An extensive review of screening tools for
PIMs and polypharmacy in the context of geriatric oncol
ogy is beyond the scope of this review but has been
described elsewhere.3,8
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Table 1 Healthcare Provider Tasks Associated with Managing Polypharmacy in Older Adults with Cancer Across Different Healthcare
Settings
Practice
Setting
Academic
Medical
Center
Inpatient
Setting

Pharmacy Tasks

●

●

of admission to hospital, espe
cially for patients admitted
through the emergency
department.
Involve patients and caregivers
in the deprescribing process
(eg, keep patients up-to-date on
any medication changes).
Promote awareness of depre
scribing services on the inpati
ent units (eg, market services to
providers and patients alike).
Champion the formation of an
Oncology-Acute Care for
Elders unit with a focus on
polypharmacy assessment.

●

●

prescribing inertia (eg, if reason
for admission is due to compli
cations from a fall, medications
should always be considered
a potential contributing factor).
Promote awareness of depre
scribing services on the inpati
ent units (eg, recommend
available pharmacists services to
patients and caregivers).
Work with an interprofessional
team to flag barriers to depre
scribing (eg, inability to coordi
nate with outside specialist
physicians).

●

●

proactive assess
ments of potentially inap
propriate medication therapies
(eg, bring concerns to phar
macists and providers as soon
as possible).
Collaborate with pharmacy
staff in potential OncologyAcute Care for Elders
rounding.
Utilize tools to complete
screening for delirium and falls.

● Continuation of inappropriate

●

●

therapies is common in the
hospital setting; breaking pre
scribing inertia can successfully
occur during hospital
admissions.
Interprofessional team resources
are necessary to manage falls and
delirium related to inappropriate
medication therapies.
Deprescribing is feasible during
a hospital stay; therefore, clini
cians should promote awareness
of the available service to col
leagues, patients, and caregivers.

tion reconciliation (drug name,
strength, route, frequency,
duration, indication) using the
patient provided list, electronic
medical record, records from
outside pharmacy and claims
data.
Assess medication adherence.

●

of the reconciled medication list
using the patient provided list,
electronic medical record.
Collaborate with an interprofes
sional team (eg, licensed inde
pendent practitioners,
pharmacists, nurses, social
work) to optimize medication
use.

from a comprehensive medica
tion review.

●

●

talizations and emergency
department visits.
Develop a process for conduct
ing periodic comprehensive
medication reviews for patients
in need.
Evaluate cancer-related medica
tions and medications for other
comorbid conditions.

● Perform comprehensive medica ● Ensure that medications have ● Promote proactive medication ● Develop a process for perform

●

Infusion
Center
Setting

Bottom Line
Recommendation

● Perform comprehensive medica ● Perform an independent review ● Flag patients that may benefit ● Aim to deter preventable hospi

●

Surgical
Oncology
Setting

Nursing Tasks

● Flag prescribing inertia at time ● Recognize common instances of ● Promote

●

Academic
Medical
Center
Ambulatory
Care Setting

Provider Tasks

tion review in order to optimize
medication use (eg, assessing
indication, limiting side effects,
limiting drug–drug interactions,
assessing cost, limiting pill
burden).
Assess the need to discontinue
certain high-risk medications
before surgery (eg, fall-inducing
medications, delirium-inducing
medications, medications that
increase bleeding risk).

been reviewed prior to the sur
gery in order to reduce the risk
of post-surgical adverse events
(eg, falls, delirium).

reviews for patients.
collaboratively with
pharmacy staff to optimize
medication use (eg, communi
cating pill burden, side effects,
patient specific factors).
Recognize and screen for med
ications associated with delir
ium and falls.
Communicate
medication
changes, discontinuations or
new prescriptions with
patients upon discharge.

● Work

●

●

●

ing comprehensive medication
reviews as a routine part of the
pre-surgical assessment.
Multidisciplinary resources are
necessary to manage falls and
delirium related to inappropri
ate medication therapies.

● Ensure cancer therapy is appro ● Assess the appropriateness of ● Assess patient before cancer ● Work with an interdisciplinary

●

●

priate based on patient’s disease,
functional age, comorbidities,
and goals of care.
Provide education to patients
regarding their regimen and
particular side effects that may
be more common based on
their functional age.
Educate infusion center staff on
ways to identify PIMs in older
adults (eg, Beer’s criteria,
STOPP/START criteria, review
high risk medications).

●

cancer therapy based on
patient’s disease, functional age,
comorbidities, and goals of care.
Evaluate effectiveness of therapy
and supportive care regimens,
and deprescribe agents in which
the risks outweigh the benefit.

●

●

therapy (infusions) to ensure
treatment parameters are met.
Ensure appropriate line access
for treatment.
Assess patient during and after
infusion, monitoring for side
effects or reactions.
Communicate
medication
changes, discontinuations, or
new prescriptions with
patients.

●

team to develop a process to
review medications and cancer
therapy to ensure treatment is
appropriate for each patient
based on their individual factors.
Communicate
medication
changes, discontinuations or
new prescriptions with patients,
while providing thorough
education.

(Continued)
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Table 1 (Continued).
Practice
Setting

Pharmacy Tasks

Community
Hospital
Setting

Nursing Tasks

Bottom Line
Recommendation

● Perform comprehensive medica ● Develop a process to double ● Promote proactive medication ● Collaborate with an interprofes

●

●

tion review in order to optimize
medication use and minimize risk
of adverse drug events (eg,
assessing indication, limiting side
effects, limiting drug–drug inter
actions, assessing cost, limiting pill
burden)
Evaluate cancer-related medica
tions and medications for other
comorbid conditions.
Ensure chemotherapy orders
are verified appropriately based
on appropriate dosing and per
tinent laboratory values.

check the appropriateness of
cancer therapy based on
patient’s disease, functional age,
comorbidities, and goals of care.

reviews for patients.
collaboratively with
pharmacy staff to optimize
medication use (eg, communi
cating pill burden, side effects,
patient specific factors).
Communicate
medication
changes, discontinuations or
new prescriptions with
patients upon discharge.

sional team to ensure cancer
therapy and supportive care
regimens are appropriate.

● Work

●

● Align medication decisions with ● Deprescribe medications based ● Monitor for signs of new med ● Align medication therapies with

Palliative
Care and
Hospice
Setting

●

●

Specialty
Pharmacy
Setting

knowledge of patient life expec
tancy and individual medication
goals (eg, avoidance of sedating
medications early in the day to
promote alertness).
Consider patient’s ability to
swallow or chew and the
impact on medication dosage
form decisions (eg, loss of oral
access necessitating sublingual
administration).
Approach deprescribing deci
sions systemically in an effort
to minimize deprescribing fail
ures and unwanted hospital
readmissions; support decisions
using standardized deprescribing
frameworks.

●

●

on remaining life expectancy of
the patient, time until benefit of
the medication, individual
patient goals of care, and the
intended target of the
treatment.
Establish roles and responsibil
ities of deprescribing efforts
amongst provider colleagues (eg,
assigning ownership to primary
care provider versus
oncologist).
Empower nursing colleagues to
take the lead in flagging medica
tion related problems; empower
through communication and
protocol development.

●

●

●

ication adverse effects or
withdrawal symptoms after
deprescribing.
Educate patients and caregivers
on potential medication
adjustments, monitoring, and
the appropriate use of “emer
gent” therapies.
Consider patient’s ability to
swallow or chew and the
impact on medication dosage
form decisions (eg, loss of oral
access necessitating sublingual
administration).
Collaborate with pharmacists
to develop rationale for medi
cation management to present
to the team.

●

●

goals of care, particularly utiliz
ing therapies that improve or
maintain quality of life.
Utilize strategies for deprescrib
ing that prevent medication
withdrawal and unwanted emer
gency department visits and
hospital readmissions.
Explore the role of nurses in
medication management in the
palliative and hospice setting,
particularly nursing-pharmacist
collaboration.

● Perform comprehensive medica ● Assess the appropriateness of ● Collaborate and communicate ● Collaborate with an interprofes

●
●

●
●

104

Provider Tasks

tion review in order to optimize
medication use and minimize the
use of
PIMs.
Educate patient regarding che
motherapy and/or supportive
care regimens, highlighting side
effects or special considerations
(eg, drug storage, how medica
tion is best taken).
Discuss affordability and ensure
delivery of medications.
Assess medication adherence by
talking with the patient and
reviewing refill history.
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●

cancer therapy based on
patient’s disease, functional age,
comorbidities, and goals of care.
Communicate with specialty
pharmacy staff when changes
occur in the patient’s cancer
regimen (eg, dosage changes,
start of new medications, dis
continuation of medications).

●

with specialty pharmacy staff
regarding medication changes,
discontinuations or new
prescriptions.
Promote
medication
adherence.

sional team to

● ensure cancer therapy and sup

●

portive care regimens are
appropriate.
Provide thorough education and
assess medication adherence
and ensure affordability and
access to medications.
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Academic Medical Center Inpatient
Setting
Many patients who are hospitalized—especially patients
with cancer—are taking multiple medications, including
medications that are no longer needed or that potentially
contribute to hospital admission or readmission.9 The
inpatient academic medical center (AMC) setting pre
sents challenges and barriers to polypharmacy assess
ment and deprescribing.10–13 For example, inappropriate
prescribing inertia is common in the inpatient setting,
and polypharmacy assessment and deprescribing are
commonly limited to reactive processes, such as in
response to an adverse drug reaction, rather than proac
tive, especially in teaching hospitals.14
But AMCs may also offer an ideal environment for
deprescribing due to the collaborative environment, time
for detailed medication histories, and engagement of
families and caregivers in the deprescribing process during
the hospital stay.15,16 For older adults with cancer, the
AMC can be an appropriate environment to study poly
pharmacy due to the multidisciplinary cancer care, focus
on education/scholarship, and longer lengths of stay.
Furthermore, research in the general geriatric population
has shown that inpatient deprescribing initiatives are fea
sible and safe and that they are successfully continued
after hospital discharge.10
There is currently a literature gap on the impact of
polypharmacy and deprescribing interventions specifically
in the AMC. The only study on the impact of
a multidisciplinary team to reduce polypharmacy in older
adults with cancer is an observational study by Flood
et al.17 The study outlined a model for combating poly
pharmacy within a novel Oncology-Acute Care for Elders
(OACE) unit that served as an interdisciplinary consulta
tion service aimed at recognizing and managing geriatric
syndromes. The OACE team consisted of bedside nursing
and a geriatric clinical nurse specialist, hospice nurse,
geriatrician, clinical pharmacist, registered dietician, social
worker, and case manager. A key component of the OACE
was formal ongoing education, provided mostly by the
clinical pharmacist, on geriatric syndromes, polypharmacy,
and the use of high-risk medications. Researchers used the
Beers Criteria to assess for PIMs and noted non-Beers
medications as high-risk based on perceived likelihood of
causing harm (eg, delirium, falls). The most commonly
prescribed PIM was diphenhydramine. Out of 47 patients
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in the study, 53% had their medication regimen altered and
about a third had a PIM discontinued. This model could be
modified even further to create an inpatient polypharmacy
consultation service or be formally integrated with inpati
ent rounding services for oncology units.
Other studies on the impact of polypharmacy in hospi
talized patients with cancer include a small pilot study by
Mort et al18 that evaluates a pharmacist-led deprescribing
intervention in hematopoietic stem cell transplant patients.
The pilot study was designed as a result of internal quality
data showing that the inpatient stem cell transplant popu
lation experienced a high incidence of falls, mostly attrib
uted to medication-related adverse effects (eg, delirium,
vasovagal falls).19 The average age of patients in this
study was 65 years old and the median length of admission
was 21 days. The major endpoints of the study included
incidence of PIMs, percentage of PIMs successfully depre
scribed, incidence of drug–drug interactions (DDIs), com
parison of home and discharge polypharmacy, and fall
events. Patients were screened for polypharmacy (≥5 med
ications) and PIMs (using sequential application of Beers,
STOPP, and the MAI) during an outpatient pre-transplant
visit. After admission, the pharmacist completed a fivestep deprescribing process. A total of 33 PIMs were iden
tified for nine patients. Of these, a total of 22 of the 33
PIMs (67%) were successfully deprescribed. Most com
mon drug classes deprescribed were analgesics and vita
mins/minerals. Sixteen drug interactions were noted, most
commonly between ciprofloxacin and vitamins/minerals.
After the deprescribing intervention for the nine patients,
polypharmacy was reduced by 11% from admission to
discharge. No patients in the study experienced a fall
event. This was the first study to apply a deprescribing
intervention in the hospital setting for patients undergoing
stem cell transplant.
Several studies have described the impact of specific
medications or medication classes on delirium in older
adults with cancer in the AMC. One study evaluating
geriatric syndromes on an OACE found that several
patients were taking high-risk medications, including
diphenhydramine to prevent infusion reactions prior to
anticancer treatments or as part of transfusion protocols.
Diphenhydramine in hospitalized older adults has been
associated with an increase in urinary retention and delir
ium. The authors noted that the majority of the OACE
patients who received diphenhydramine prior to a blood
transfusion did not have a history of any infusion
reaction.20 Another study by Gaudreau et al21 found that
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exposure to opioids, benzodiazepines, and corticosteroids
was associated with an increased risk of delirium in hos
pitalized older adults with cancer. This study did not find
an association with anticholinergic therapies and delirium
risk.
A review by Marvin and Jubraj22 explored polyphar
macy in the hospital environment in the general older adult
population and found that ordering medications was the
most common intervention that occurs in the acute care
setting. The authors identified several points of care during
a hospital stay in which a polypharmacy assessment may
occur: pre-admission to the hospital, before and after sur
gical procedures, worsening of long-term conditions, diag
nosis and treatment of a new disease alongside other
preventative therapies, and preparing for hospital dis
charge. Each of these points of care could be explored
further in older adults with cancer.
Several other studies touch upon the issue of polyphar
macy that have the potential to be new areas of research
for older adults with cancer, specifically in academic med
ical centers, including the development of health system
standard work/guidance tools for inpatient polypharmacy
management; the need for educating new clinicians and
students about polypharmacy and its harms; the role of
empowering patients to become engaged with inpatient
medication reviews; and creating awareness that depre
scribing is an option for patients in the hospital.23–28
More studies are also needed to define the potential roles
of non-pharmacist clinicians (eg, physicians, advanced
practice providers, nurses) on tackling polypharmacy. Of
note, collaborative deprescribing interventions that include
patients, physicians, and pharmacists may be more effec
tive than less-inclusive interventions.29

Academic Medical Center
Ambulatory Care Setting
Several barriers to polypharmacy assessment may exist in
the AMC outpatient setting compared to the inpatient
setting, including clinicians having less available time
to spend with the patient and fewer personnel being
available to complete the medication review. But the
ambulatory setting within an AMC provides multiple
opportunities to assess polypharmacy and other medica
tion-related concerns in older adults with cancer. These
opportunities include medication review by a nurse or
doctor during a routine oncology visit; a targeted review
by a pharmacist integrated into the oncology clinic; and
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a polypharmacy assessment in a multidisciplinary clinic
that includes a pharmacist. Exactly when and how to
incorporate the polypharmacy-related medication review,
however, can vary.
Studies have demonstrated different approaches to
accomplishing polypharmacy assessment in older adults
with cancer in the ambulatory setting. In one pilot study
by Ramsdale et al,30 older adults with cancer were admi
nistered a geriatric assessment (the provider performing
the polypharmacy assessment was not indicated) and then
the patient’s oncologist either received the polypharmacy
recommendations and was provided time to discuss them
with the patient (intervention group) or they did not
receive the recommendations (control). Despite the small
number of patients (n=40), the assessment identified
a significant number of polypharmacy-related concerns.
The majority of polypharmacy concerns centered around
supportive care (51% vs 27%, respectively) but it is also
worth noting that there was a notable difference in the
discussion surrounding treatment for other comorbidities
outside of cancer in the intervention arm (52% vs 31%).
The fact that comorbidities were not discussed as often in
the control arm could imply that providers may be limited
with time and therefore unable to address polypharmacy
during a routine visit. Additionally, the findings indicate
that polypharmacy is more likely to be addressed if the
medication review can be done ahead of time or by
another provider, such as a pharmacist, since routine visits
rarely allow time for such assessment by the oncologist.
Other research similarly indicates the benefits of sche
duling time for a medication review that occurs separately
from other medical care. Yeoh et al examined the impact
of a medication therapy management (MTM) service for
ambulatory patients who were 65 or older and found that
the clinical pharmacist performing the medication review
with a validated screening tool identified a drug-related
problem in at least 90% of the patients who took one or
more chronic medications.31 The pharmacist intervened on
44 of the 361 identified drug-related problems, with most
interventions rating some degree of significance (ranging
from minor significance to very significant). These find
ings indicate that any older adult with cancer who is taking
at least one medication is a good candidate for a more
detailed polypharmacy assessment with a screening tool.
Several studies have compared the tools used to assess
polypharmacy in older adults in the ambulatory
setting,32,33 but few have investigated which tools are
best suited for those with cancer. One study by Whitman
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et al compared the use of 12 screening assessments in
older adults with cancer and found that while many of
the screening tools detected PIMs, these medications may
actually be benefiting the patient and therefore must be
considered within the overall context.8 The authors con
cluded that there is a lack of polypharmacy assessment and
deprescribing protocols available to target the unique
population that is older adults with cancer. The findings
also lend support to having a pharmacist perform the
medication review, select the most appropriate screening
tools, and interpret their findings.
Findings of other studies have also demonstrated the
benefit of using pharmacists to perform medication
reviews. For instance, a study by Nightingale et al found
that some screening tools are best used in combination (eg,
Beers and STOPP) to capture a larger prevalence of poly
pharmacy that can then be intervened upon.6 When
a pharmacist, trained to be familiar with the context and
indications for a medication, used a combination of vali
dated screening tools, more PIMs were identified and
rectified. This recommendation is supported by the find
ings of a pilot study by Whitman et al in which
a pharmacist implemented a comprehensive geriatric
assessment of up-to-date and accurate medication lists
(including prescription, non-prescription, and supple
ments/complementary alternative medications) for older
adults with cancer in the outpatient setting.5 The assess
ment utilized three screening tools, applied in the follow
ing order, as the scope of each one narrows: the Beers
Criteria, Screening Tool to Alert doctors to Right
Treatment (START), STOPP, and the MAI. The authors
concluded that use of all three screening tools uncovered
three times more drug therapy problems than any single
tool alone and produced the most efficient strategy to
identify inappropriate medication use. The authors also
noted that supplemental screening tools, such as the
Choosing Wisely Initiative and the Canadian
Deprescribing Network, can further assist providers with
addressing polypharmacy in older adults with cancer.
Literature supports integrating a pharmacist into ambu
latory healthcare teams. A study by Valgus et al evaluated
patients’ palliative symptom scores over time following
integration of a clinical pharmacist on an oncological
multidisciplinary team in the outpatient setting.34 The
study had a limited number of patients (n=89), with only
19 older than 60 years old. The pharmacists in the study
obtained cognitive assessments, gathered medication his
tories, and assigned palliative assessment scores. Patient
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symptom evaluation was limited to palliative symptoms,
not all comorbid conditions. Still, when the researchers
compared the symptom scores to those from the inpatient
setting, the scores in the outpatient setting improved after
a pharmacist was included on the team, highlighting the
value of a pharmacist-embedded in the multidisciplinary
approach to treating patients.
In similar study by Mancini, a pharmacist in
a multidisciplinary oncology clinic assessed the medica
tions for adult outpatients with cancer and identified dupli
cate therapies (46.7% of patients), drug interactions (44%),
side effects (74.7%), lack of efficacy (94.7%), and
untreated conditions (73.3%).35 The authors concluded
that a pharmacist can bring value to an outpatient team
and help other practitioners with their assessments. Again,
their findings support pharmacists in the medication
review role, but because the population under investigation
was not older adult-specific, this study did not provide
direct evidence of their value for assessing polypharmacy
in older adults with cancer in the ambulatory setting.
A recent study by Choukroun et al highlights the
importance of collaboration among different providers
for reducing polypharmacy and inappropriate medication
use.36 The prospective study evaluated the impact of hav
ing a pharmacist and a geriatrician each perform a separate
medication review as part of a geriatric assessment in
older adults (median age: 83 years) with solid tumor
malignancies and an average of four comorbidities. The
notable difference between the pharmacist and geriatrician
was that the pharmacist used two validated screening tools
as part of the assessment. The pharmacists identified 165
drug therapy problems, most of which were moderately
(49%) or most severe (0.8%). The authors concluded that
adding a pharmacist to a geriatrician’s team resulted in
identification of more drug-related problems versus the
experienced clinician conducting the medication review
alone.
Another study by Watkins et al examined the feasibility
of having pharmacists document MTM activities and sub
sequently bill for the service.37 The pharmacists, who were
already integrated within the ambulatory clinics at the
comprehensive cancer center, performed 239 MTM visits
over 3 months with patients (average age = 56 ± 13 years)
who had an oncological diagnosis and at least two other
comorbidities. Many of the visits were initiated due to
cancer-related concerns, but this opened the door to assess
ment of the patient’s other comorbidities so that the patient
received a comprehensive evaluation from a medication
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perspective. Implementing the formal MTM documenta
tion and billing process increased the perceived value and
visibility of the pharmacist services to the cancer center.
These findings also highlight the importance of addressing
not only the primary cancer but also the other comorbid
ities that patients may be experiencing. Although not spe
cifically reported in this article or other available literature,
it can be speculated that medication evaluation beyond
cancer treatment could translate into a reduced risk of
hospital admission secondary to poor management of
other disease states. More literature specifically on older
patients with cancer is needed.
In the ambulatory setting, there are many opportunities
for patients to interact with a variety of healthcare profes
sions. Plenty of data support integration of a pharmacist
into the geriatric assessment of older adults with cancer,
similar to inpatient oncology polypharmacy assessment,
but it is unclear how pharmacists can best support and be
supported by other members of the team for a true multi
disciplinary approach that optimizes the care of older
adults with cancer. Furthermore, a literature gap exists on
how to best utilize non-pharmacists members of the ambu
latory healthcare team in geriatric assessment. There
would also be potential benefit in evaluating older adults
with cancer from not only an oncological perspective but
also from a cancer plus comorbidity perspective to
enhance quality of life and decrease potential adverse
effects.

Surgical Oncology Setting
The importance of assessing polypharmacy in older adults
with cancer also applies to surgical oncology as emerging
evidence suggests that polypharmacy and PIM use are
significantly associated with postoperative outcomes (eg,
postoperative complications, delirium, extended length of
hospitalization, and emergency department visits). Thus,
a unique opportunity exists for members of the interpro
fessional surgical oncology healthcare team to optimize
medication use in order to positively impact patient care.
A retrospective cohort study by Jeong et al evaluated
associations between preoperative medication use and
postoperative length of hospital stay in older adults under
going cancer surgery.38 An interprofessional care team,
consisting of geriatricians, nurse specialists, dietitians,
and pharmacists, conducted a comprehensive preoperative
geriatric assessment. The pharmacists were responsible for
performing the medication assessment and evaluating all
prescription and non-prescription medications, including
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using the 2015 Beers criteria to analyze the number of
medications, delirium-inducing medications, fall-inducing
medications, and PIMs. The study reported that cancer
type and the number of medications, PIMs, and deliriuminducing medications were statistically significant factors
for postoperative length of stay. A similar retrospective
study by Choi et al examined the relationship between
preoperative medication use and postoperative institutio
nalization and death in older adults with cancer.39 The
study showed that polypharmacy, infection, and transfu
sions—identified on a preoperative comprehensive geria
tric assessment conducted by an interprofessional care
team, including pharmacists conducting the medication
evaluation—were significantly associated with postdischarge institutionalization after adjusting for confoun
ders. A study by Westley et al investigated rates and
associated predictors of emergency department visits in
older women 45-days post breast cancer surgery.40 Some
of the significant factors associated with emergency
department visits were cancer stage, mastectomy, poly
pharmacy, benzodiazepine and anticoagulant use, and
past hospitalization. The authors concluded that some of
these factors could potentially be mitigated and amenable
to early intervention. Another study by Jeon et al exam
ined the association between preoperative medication use
and hospital readmission.41 The authors reported that pre
operative discontinuation-requiring medications (defined
as medications that should be discontinued before surgery
due to surgical risks, such as antithrombotic agents for
postoperative hemorrhage, metformin for lactic acidosis,
and herbal medications for the uncertainty about their
actual contents) were associated with unplanned 30-day
hospital readmission after surgery, despite discontinuing
medications.
The International Society of Geriatric Oncology devel
oped a Surgical Taskforce that conducted a survey to
explore surgical oncologists’ approach towards surgery in
older adults with cancer, given the ongoing uncertainty
around cancer management, including under-treatment
and overtreatment.42 The survey reported a low overall
response rate (11%, n=251) and revealed that only 6.4%
of the surgeons who responded used a comprehensive
geriatric assessment in daily practice. Additionally, colla
boration with geriatricians was uncommon, despite the fact
that patient quality of life and functional recovery were
identified as some of the most important and relevant
endpoints in this population.
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Combined, this information presents an opportunity for
oncology surgery service lines to reimagine how interpro
fessional team members and resources can be utilized to
improve patient outcomes. Little research has focused on
medication interventions to reduce polypharmacy and opti
mize medication management in older adults with cancer
in the surgical oncology (preoperative) setting.5,6,43–46 But
it is clear that medication management is a critical com
ponent of the preoperative screening assessment and the
postoperative monitoring process. At a minimum, preo
perative medication assessments should consist of an eva
luation for polypharmacy and inappropriate polypharmacy.
Inappropriate polypharmacy can be screened utilizing
tools such as Beers criteria47 or the STOPP criteria.48
Both delirium- and fall-inducing medications should be
identified, with indications for use, so potential deprescrib
ing could be initiated. In such cases, deprescribing could
consist of dose tapering, switching to as-needed use, or
abrupt discontinuation with pre-determined monitoring
parameters for close follow-up. Additional medications
that should be assessed and discontinued as part of the
preoperative process include antithrombotic agents due to
risk for hemorrhage, metformin due to risk for lactic
acidosis, exogenous hormones due to risk for thrombosis,
and herbal medications due to uncertainty around actual
contents and risk for drug–herb interactions.38
Delivering comprehensive medication management
services within a surgical oncology practice environment
does require significant resources, including staff/person
nel, time, finances and leadership to oversee this highquality service. Although these resources may add costs
and time to care initially, they may also provide valuable
benefits postoperatively in the form of improved patient
outcomes and reduced readmissions rates.

Infusion Center Setting
In infusion centers, pharmacists are involved in the pre
paration and dispensing of chemotherapy regimens, and
they also have the opportunity to play a role in identifying
PIMs in older adults with cancer. It is important for these
pharmacists to be aware of not only a patient’s chronolo
gical age but also a patient’s functional age when assessing
appropriateness of the patients’ regimens. In 2018, the
Hematology/Oncology Pharmacy Association published
guidelines that further defined the scope of hematology/
oncology practice for pharmacists, including the role of
infusion center pharmacists.49 The document outlines
important tasks of the infusion center pharmacist,
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including upholding, maintaining regulation requirements,
and reviewing a patient’s cancer treatment plan through
verification and dispensing processes. The document does
not, however, address concerns related to older patients
with cancer.
Limited research has explored the role of infusion
center pharmacists in medication use and assessment. In
a prospective, descriptive, cross-sectional study by Knez
et al, pharmacists in a chemotherapy preparation unit were
shadowed to evaluate the clinical interventions they made
related to the dispensing of chemotherapy doses.50 The
problems that the pharmacist identified as requiring an
intervention mostly related to “drug and therapy” (38%),
“clerical” (33%), or “dose, frequency, and duration”
(19%). The oncologist accepted most pharmacist recom
mendations, implementing them in 86% of the cases.
These findings highlight the important role of pharmacists
in reviewing the treatment plan and dispensing of the
chemotherapy in order to provide quality care to patients
with cancer. The study did not discuss the importance of
a full medication review that included reviewing
a patient’s non-cancer medication regimen, particularly in
the older cancer patient population (patients in this study
ranged in age from 24 to 75 years).
A retrospective cohort study by Sokol et al aimed to
identify the potential for adverse drug reactions and to
define physicians’ responses to potential DDIs in patients
at least 70 years of age with multiple comorbidities and
also receiving chemotherapy. On average, patients had
three comorbid conditions, most commonly cardiovascu
lar, pulmonary, and gastrointestinal conditions. The results
showed that polypharmacy was prevalent in these patients,
as they took an average of nine medications (prescription
and non-prescription), most commonly medications for
treating cardiovascular and gastrointestinal comorbidities. Despite the potential for DDIs, physicians
made no adjustments to prescriptions.51
Additional studies are needed to further define the role
of the pharmacist in the infusion center setting, particu
larly related to polypharmacy and the care of older adults
with cancer. Likewise, studies could also be conducted to
define the role of other healthcare providers and how to
best collaborate in the infusion center setting.

Community Hospital Setting
Community cancer centers differ from larger AMCs and
designated cancer cancers in regard to resources and staff.
In particular, community cancer centers often lack
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a clinical pharmacist who can provide medication assess
ment specific to the issues facing patients with cancer. The
literature describing older adult cancer care provided at
community hospitals is scarce, especially studies reporting
on medication use and polypharmacy. A retrospective
study by Loui et al demonstrated that complex oncologic
resections (defined as esophagogastric, hepatobiliary, pan
creatic, rectal, and retroperitoneal resections) could be
safely performed at community hospitals.52 Of the patients
evaluated, 88 (64.7%) were male and average age was
65.6 years. The mortality rate was 0.7% (grade
V complication), the median length of stay for all opera
tions was 8 days, and the hospital readmission rate within
30 days of initial discharge was 2.9%. The authors did not
discuss medication assessments nor did they discuss inap
propriate polypharmacy, delirium or falls as part of the
study outcomes. A similar study by Hardacre et al evalu
ated 60-day outcomes associated with a pancreatic surgery
program at a 144-bed community, non-teaching hospital
compared to a tertiary medical center.53 The authors
reported that there were no mortalities at either hospital,
and major complications, reoperation rates, and readmis
sion rates did not differ between the two hospitals.53 They
did not report preoperative medication assessments nor
delirium or falls as part of the study outcomes.
A study by Chung et al reported on a practice model
change within a community hospital aimed to meet quality
and safety goals.54 The practice change involved an inter
professional team of nurses, pharmacists, and physicians
that developed standardized order sets, protocols, opera
tions, and chemotherapy, along with collaborative practice
agreements. This practice model change resulted in a 45%
reduction in chemotherapy errors and found that the most
common cause of errors was missing information (eg,
omission of drug duration or frequency, dose, route, or
premedication). The pharmacists reported that, prior to the
practice model change, they did not feel empowered to
make clinical recommendations on dose modification or
provide specific oncology drug information, and after the
changes were implemented, they had the tools to perform
clinical monitoring and communicate recommendations to
oncology physicians and providers.54 This study did not
include information on structured medication assessments
for non-chemotherapy drugs and did not report how the
practice model change influenced patient outcomes.
We also uncovered literature on the development of
a senior adult oncology program within a community can
cer center. A pilot study by Lynch et al described the
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development of a specialized program for older adults
within a community cancer center.55 The program was
designed to identify and treat cancer and comorbidities,
geriatric syndromes such as malnutrition and polyphar
macy, and educate patients, families, and the community,
among other goals.55 It consisted of a unique model of
service including a nursing assessment, social work eva
luation, psychological evaluation, nutrition counseling,
and prescription guidance, however the program did not
mention whether a pharmacist was a member of the inter
professional care team. The patients who participated in
the pilot experienced a variety of medical issues, with the
most common related to nutrition (n=19) and medication
assistance (n=130).55 Details regarding polypharmacy
were not included, and medication-related interventions
were not reported.
Recognizing that community cancer centers may not
have the same amount of resources or number of cancer
care providers, specialists, and allied healthcare profes
sionals (eg, clinical pharmacists, dieticians, social workers,
care navigators), few studies have evaluated the benefit of
clinical pharmacy services at a community oncology
clinic. A retrospective descriptive study by Ruder et al
analyzed the impact and cost savings of having a clinical
pharmacist on staff to consult regarding clinical interven
tions and consultations at a community oncology clinic.56
Interventions included medication reconciliation, dosing,
and side effect prevention and management, and consulta
tions involved patient visits and patient education. Of the
583 interventions reported, 131 were related to adverse
events, 52 were related to medication reconciliation, and
22 were dose-related. Patient et al surveys revealed posi
tive ratings for clinical pharmacy services.56 This study
did not report patient demographic information, such as
median age, and did not include information on polyphar
macy and inappropriate polypharmacy. The study did,
however, demonstrate that the presence of a clinical phar
macist (versus a pharmacist who is solely responsible for
admixing and dispensing parenteral chemotherapy) opens
up opportunities to optimize the quality of cancer care for
patients and to improve drug information and education to
fellow healthcare providers.

Palliative Care and Hospice Setting
Many clinicians are daunted by the prospect of managing
polypharmacy and PIMs in persons who are nearing or are
at the end of life.57 Cancer care and medication manage
ment in this population is complex due to a number of
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different factors. These include a rise in the number of
comorbidities at the end of life, an increase in the potential
for medication adverse effects and geriatric syndromes,
conflicting goals of care between providers and patients,
and poor approximation of life expectancy. The incidence
of PIM use in older adults with cancer, specifically in the
palliative care and hospice settings, has been found to
range from 22% to 95%.58 However, the criteria for PIM
identification, as well as the process for deprescribing, are
inconsistent between studies. Outcomes data are also
sparse in this population.59–61
Despite these limitations, several deprescribing frame
works have been developed that provide an opportunity for
future research in older adults with cancer. A framework
developed by Lindsay et al62 aims specifically to assist
clinicians in recognizing PIMs and guide rational depre
scribing in palliative oncology patients. Called OncPal, the
guideline is geared towards patients with a life expectancy
of less than 6 months; therefore, it is applicable in both the
palliative and hospice settings. The initial study compared
the use of the OncPal Deprescribing Guideline to expert
assessment (palliative care, radiation oncology, and medi
cal oncology clinicians) and found that the OncPal guide
line assessed PIMs correctly 94% of the time
comparatively. The incidence of PIMs in this study was
70%, with the most frequently flagged drug classes for
deprescribing intervention being antihypertensives, dysli
pidemic agents, and complementary and alternative thera
pies. The medication class found to be the most discordant
between the OncPal guideline and the expert panel was
neoplastic/immunomodulator oral anticancer treatments.
Preliminary data suggest an important role of the OncPal
deprescribing guideline, yet additional studies are needed
to validate its use in different care settings.
The Good Palliative-Geriatric Practice (GP-GP) algo
rithm is a well-validated tool potentially applicable to
older adults with cancer in the palliative care setting.
The tool consists of a number of targeted statements
questioning medication appropriateness. An initial study
by Garfinkel63 using the GP-GP algorithm focused on
reducing polypharmacy in older adults in geriatric inpa
tient units. The algorithm was applied in 119 patients
(intervention group) versus 71 patients in a control, nonintervention group. A total of 332 medications were
deprescribed in the 119 patients, averaging 2.8 medica
tions per patient, and the rate of deprescribing failure was
10%. The 1-year mortality rate was 21% in the interven
tion group versus 45% in the control group, and the rate
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of referral to a higher level of care was 11.8% in the
intervention group versus 30% in the control group.63
A subsequent study by Garfinkel64 validated the use of
the GP-GP algorithm in community-dwelling older
adults. This study excluded patients with advanced dis
ease (including cancer), thus reducing generalizability to
the geriatric oncology population. Finally, a study by
Bilek et al65 found that providing physicians a one-day
workshop on the use of the GP-GP algorithm successfully
promoted deprescribing efforts in both the inpatient and
outpatient setting. Trained physicians had a high inci
dence of deprescribing benzodiazepines, psychotropics,
and antihypertensives. About a quarter of patients in this
study were older adults with cancer.
A deprescribing framework by Holmes et al66 has been
applied to older adults with cancer. This model uses four
“pillars” of medication appropriateness to determine correct
prescribing and deprescribing: remaining life expectancy of
the patient, time until benefit of the medication, individual
patient goals of care, and the intended target of the treatment
(eg, palliative in nature vs preventative care). The framework
by Holmes et al66 has been utilized in at least one study in
older adults with cancer.5 This study was multidisciplinary in
nature and included input on the four components of medica
tion appropriateness by a geriatric oncologist, pharmacist,
nurse, physical therapist, and patients/caregivers.
In addition to applicable frameworks in the palliative
oncology population, specific studies have assessed the
impact of reducing pill burden and eliminating unneces
sary medications in the hospice setting and in patients
imminently dying of cancer.67,68 A study from 2009 by
Riechelman et al found that one in five ambulatory
patients with cancer with an estimated life expectancy of
2 months or less were taking a “futile” medication.59 The
authors defined medically futile as “an intervention that no
longer provides patient benefit, does not achieve
a valuable goal, has a potential for harm and lacks benefits
to justify resources” and retrospectively reviewed the med
ication lists of 372 older patients with cancer who were
seen in a palliative care clinic and evaluated whether the
medications they were taking were indeed futile. They
found that 22% (n=82) of the patients were taking at
least one futile medication at the end of life.
A retrospective review by DeAngelis et al assessed con
tributing factors potentially leading to hospital readmission in
75 patients admitted to hospice. The authors identified three
main reasons for readmission: medication-related problems,
unanticipated new medical problems, and uncontrolled
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symptoms. Interestingly, 33 of the patients (45%) presented
with uncontrolled symptoms, thereby requiring reinitiating
therapy previously deprescribed upon hospice admission.69
The conclusions of this study are supported by two
others,70,71 but despite this, few studies have reported out
comes of inappropriate deprescribing in the hospice
population.
There is a gap in the literature describing which
member(s) of the healthcare team are best equipped to
manage polypharmacy and PIMs in this population. In
one study that touches upon the concepts of older adults
with cancer, polypharmacy, and chronic disease state man
agement at the end of life, the authors point out that the
general practitioner is often unwilling to alter cancerrelated treatment, and in turn the oncologist is often
unwilling to alter any non-cancer-related treatment,
thereby putting the patient at risk of continued polyphar
macy with potential adverse outcomes.72 The findings of
the study highlight that polypharmacy is often not
addressed until the end of life and beg the question
“whose responsibility is it to address polypharmacy?”
The authors conclude that a patient’s primary care physi
cian should be assessing polypharmacy prior to the end-oflife phase of care.
Huisman et al recently explored the role of the hospice
nurse in medication management and deprescribing
interventions.73 The authors performed a qualitative interview
study to summarize perspectives of patients, caregivers, and
healthcare providers on the nurse’s role in medication manage
ment in the hospice setting. The study was a secondary ana
lysis for the “MEDIcation management in the LAST phase of
life (MEDILAST)” study. The authors performed 76 inter
views with patients (n=17), nurses (n=20), medical trainees
(n=20), informal caregivers (n=12), and family physicians
(n=12), and the recorded interviews were analyzed and
coded based on relevancy. The notable emerging themes iden
tified via the interviews included the nurse’s role in identifying
medication burden at the end of life; educating the patient on
medication adjustments and the monitoring that will follow;
monitoring for medication side effects; and the direct impact
on quality of life. The interviews revealed that the hospice
nurse plays a role in delegating medication management to the
caregiver in some cases and in keeping them educated on
when to administer “emergent” medications. Additionally,
the hospice nurse can propose changes in medication therapy,
such as the route of administration when the patient is no
longer able to swallow, and empower the patient and care
givers on as-needed medication administration. Ultimately, the
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authors concluded that the nurse plays a large role in the
patient’s end-of-life medication management and quality of
life.
In summary, based on available information, medication
management roles for pharmacists, providers, and nurses
appear balanced in the palliative oncology and hospice set
tings. For future studies, existing frameworks in palliative
oncology should be utilized and compared across different
cancer care settings, particularly emphasizing outcomes of
deprescribing and deprescribing failure.

Specialty Pharmacy Setting
Specialty pharmacies have grown immensely over the past
four decades, establishing their role in healthcare delivery.
These pharmacies are able to work with providers and
insurers alike to ensure patient access to therapy and to
address issues regarding financing and delivery of the
medication, including oncology medications.74 However,
as these pharmacies have become more popular, patients
may fill their medications at multiple pharmacies.
Inadequate communication among pharmacies and provi
ders may lead to therapeutic duplication or prescribing of
medications with significant DDIs.75 This lack of commu
nication among health care professionals may be particu
larly problematic for older adults with cancer who often
have multiple chronic conditions and take many
medications.76
There are limited data regarding polypharmacy in older
adults with cancer utilizing specialty pharmacies.
However, according to the National Comprehensive
Cancer Network Specialty Pharmacy Task Force, the pri
mary goals of specialty pharmacies are to ensure the
appropriate use of medications, maximize drug adherence,
enhance patient satisfaction through direct interaction with
healthcare professionals, minimize cost impact, and opti
mize pharmaceutical care outcomes and delivery of
information.77 These goals can be further defined to
apply to older patients with cancer. For example, ensuring
the appropriate use of medications may include the use of
tools such as the Beer’s criteria, STOPP/START criteria
and the MAI.77 Nonadherence to medication therapy can
occur in all patient populations, but is particularly com
mon in the older adult population because they have a high
number of comorbid conditions.78 In patients with cancer,
adherence to their anticancer and supportive care regimens
is imperative to the success of their treatment course.
Therefore, in older adults with cancer utilizing specialty
pharmacies, the ability to assess and address nonadherence
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is particularly important. A retrospective analysis of
a specialty pharmacy program by Tschida et al compared
patients who used specialty pharmacies to those who used
retail pharmacies for their oral cancer regimen.79
Pharmacist involvement included biweekly phone calls
with the patients to assess adherence, provide education,
and manage side effects. The study showed that the use of
specialty pharmacy was associated with improved oral
oncology medication adherence, as well as a decrease in
healthcare costs. However, identifying drug–drug interac
tions, reviewing a patients’ non-cancer medications, and
assessing polypharmacy was not discussed in the study.
When a cancer patient utilizes a specialty pharmacy,
that pharmacy takes on an integral role in the care of
these patients as they may communicate with the patient
regularly regarding their anticancer or supportive care
regimen, including discussion of adverse events and
toxicities. However, the use of specialty pharmacies
could contribute to siloes or fragmented healthcare. It
is imperative that specialty pharmacies communicate
effectively and relay relevant information gleaned from
their patient interactions to the patient’s entire oncology
team. This communication creates an opportunity for
those involved in the care of these oncology patients to
collaborate with specialty pharmacies to ensure that
a patient has continued access to their medication and
that therapy adjustments, including temporarily holding
therapy, are appropriately communicated. Additionally,
there may be a unique opportunity for all involved to
ensure that a patient’s therapy is appropriate not only for
their chronological age but also their functional age
including their unique social, psychosocial, and financial
situations.

Conclusion
Existing data suggest a variety of clinician roles in managing
polypharmacy and other medication-related problems in
older adults with cancer. The impact of clinical pharmacists
in this population is particularly evident in the academic
inpatient, ambulatory, and palliative care settings. The extent
of non-pharmacist clinician involvement varies significantly
based on the care setting. Established themes for providers
related to polypharmacy and deprescribing interventions
include the need for enhanced awareness of potential harms
of high-risk medications and the need for breaking patterns
of inappropriate prescribing in all care settings. Studies eval
uating nursing care suggest positive roles for empowering
patients to bring forth medication concerns to their providers,
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flagging new potential medication side effects, and collabor
ating closely with pharmacy colleagues. Future studies are
needed to determine ideal processes for polypharmacy
assessment and deprescribing in the infusion center, specialty
pharmacy, and surgical oncology settings, in particular.
Additionally, structured studies are needed that examine the
current state of polypharmacy education in healthcare across
all health professions.
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